| Treatment# | Cases | Controls | OR (95% CI) | p-value |
| Inhaled antibiotics | ||||
| 1 year before | 15/30 (50.0) | 35/58 (60.3) | 0.7 (0.3–1.6) | 0.4 |
| 2 years before | 18/29 (62.1) | 22/49 (44.9) | 1.9 (0.7– 4.9) | 0.2 |
| 3 years before | 12/24 (50.0) | 15/41 (36.6) | 1.8 (0.6– 5.3) | 0.3 |
| 4 years before | 8/21 (38.1) | 13/37 (35.1) | 1.1 (0.4– 3.2) | 0.3 |
| Inhaled rhDnase | ||||
| 1 year before | 18/30 (60.0) | 32/58 (55.2) | 1.3 (0.5–3.7) | 0.6 |
| 2 years before | 19/29 (65.5) | 27/49 (55.1) | 1.6 (0.6– 4.6) | 0.4 |
| 3 years before | 13/24 (54.2) | 19/41 (46.3) | 1.3 (0.4– 3.9) | 0.6 |
| 4 years before | 13/21 (61.9) | 21/37 (56.8) | 1.2 (0.3– 4.6) | 0.3 |
| Inhaled steroids | ||||
| 1 year before | 8/30 (26.7) | 26/58 (44.8) | 0.4 (0.1–1.2) | 0.08 |
| 2 years before | 11/29 (37.9) | 21/49 (42.9) | 0.8 (0.3–2.2) | 0.7 |
| 3 years before | 11/24 (45.8) | 18/41 (43.9) | 1.1 (0.4–3.5) | 0.6 |
| 4 years before¶ | 3/21 (14.3) | 15/37 (40.6) | ||
| Low-dose azithromycin | ||||
| 1 year before | 10/28 (35.7) | 23/58 (39.7) | 0.9 (0.3–2.3) | 0.8 |
| 2 years before | 8/29 (27.6) | 20/51 (39.2) | 0.6 (0.2–1.7) | 0.4 |
| 3 years before | 3/23 (13.0) | 9/41 (22.0) | 0.4 (0.1–2.0) | 0.4 |
| 4 years before | 4/21 (19.0) | 11/37 (29.7) | 0.6 (0.2–1.9) | 0.3 |
Data are presented as n/N (%), unless otherwise stated. #: at least three consecutive months; ¶: the log-likelihood ratio test was not applicable because there were no nonexposed cases matched to exposed controls.